周四盘中，Tyra Biosciences, Inc.（股票代码：TYRA）股价大涨5.27%，引发市场关注。
消息面上，Tyra Biosciences宣布其2期临床研究Beach301取得重要进展。该公司表示，研究中首位儿童患者已接受Dabogratinib（Tyra-300）给药，这是一项针对儿童软骨发育不全症的研究。
Beach301研究是Tyra Biosciences公司重要的临床试验项目之一。软骨发育不全症是一种罕见的遗传性骨骼疾病，会导致患者身材矮小和其他健康问题。Dabogratinib（Tyra-300）作为潜在的治疗方案，若能在临床试验中取得积极结果，将为公司带来巨大的市场机遇。投资者对这一进展反应积极，推动了公司股价的上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.